Amgen (AMGN) Change in Account Payables (2009 - 2026)

Amgen's Change in Account Payables history runs 18 years deep, the most recent figure standing at $571.0 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 14.89% year-over-year to $571.0 million; the TTM figure through Mar 2026 stood at $502.0 million (down 36.13% YoY), while the FY2025 annual figure was $428.0 million, up 37.18% from the prior year.
• Change in Account Payables for Q1 2026 stood at $571.0 million, up from -$484.0 million in the prior quarter.
• The five-year high for Change in Account Payables was $643.0 million in Q2 2024, with the low at -$484.0 million in Q4 2025.
• The 5-year median for Change in Account Payables is -$44.0 million (2022), against an average of $62.5 million.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables tumbled 702.38% in 2023, then jumped 2060.87% in 2025.
• Amgen's Change in Account Payables stood at $296.0 million in 2022, then slumped by 163.18% to -$187.0 million in 2023, then decreased by 24.06% to -$232.0 million in 2024, then tumbled by 108.62% to -$484.0 million in 2025, then soared by 217.98% to $571.0 million in 2026.
• Business Quant data shows AMGN's Change in Account Payables at $571.0 million in Q1 2026, -$484.0 million in Q4 2025, and -$174.0 million in Q3 2025.